Bay Shore Trust - 15 Nov 2023 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Reporting relationship: 10%+ Owner
Issuer ticker: MIRA
Reported as of: 15 Nov 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Nov 2023, 17:09:32 UTC
Next SEC filing: 08 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Michelle Yanez, Attorney-in-Fact for Brian McNulty, Trustee

Key filing fact

Bay Shore Trust filed Form 4 for MIRA PHARMACEUTICALS, INC. (MIRA) on 17 Nov 2023.

Key facts

This page summarizes Bay Shore Trust's Form 4 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Nov 2023, 17:09.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIRA transaction Derivative

Common Stock Warrant (right to buy)

Award

Transaction value
Shares: +700,000
Change %
Price
Shares after: 700,000
Date: 15 Nov 2023
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 700,000
Exercise price: $2.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The warrants were issued to MIRALOGX LLC ("MIRALOGX"), a wholly-owned subsidiary of the Bay Shore Trust (the "Trust"), a greater than 10% owner of the Issuer, in connection with an Exclusive License Agreement, dated November 15, 2023, by and between MIRALOGX and the Issuer. The Trust may be deemed to beneficially own the shares held by MIRALOGX but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.